Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is ChangingNews DeskMay 29, 20260 Pfizer is the latest big pharmaceutical company turning to China for biotechnology innovation, striking up a cancer R&D agreement spanning…
AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood CancerNews DeskMay 28, 20260 AbbVie’s strategy of growing in oncology by focusing on a particular type of targeted therapy is paying off with another…
AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast CancerNews DeskMay 25, 20260 A Daiichi Sankyo and AstraZeneca drug is now approved as a first-line treatment for a particularly difficult-to-treat type of breast…